Abstract:Proper evaluation of therapeutic responses in Chagas disease is hampered by the prolonged persistence of antibodies to Trypanosoma cruzi measured by conventional serological tests and by the lack of sensitivity of parasitological tests. Previous studies indicated that tGPI-mucins, an α-Gal (α- d -Gal p (1→3)-β- d -Gal p (1→4)- d -GlcNAc)-rich fraction obtained from T . cruzi trypomastigotes surface coat, elicit a strong and protective antibody response in infected individuals, which disappears soon after successful treatment. The cost and technical difficulties associated with tGPI-mucins preparation, however, preclude its routine implementation in clinical settings. We herein developed a neoglycoprotein consisting of a BSA scaffold decorated with several units of a synthetic α-Gal antigenic surrogate (α- d -Gal p (1→3)-β- d -Gal p (1→4)-β- d -Glc p ). Serological responses to this reagent, termed NGP-Tri, were monitored by means of an in-house enzyme-linked immunosorbent assay (α-Gal-ELISA) in a cohort of 82 T . cruzi -infected and Benznidazole- or Nifurtimox-treated children (3 days to 16 years-old). This cohort was split into 3 groups based on the age of patients at the time of treatment initiation: Group 1 comprised 24 babies (3 days to 5 months-old; median = 26 days-old), Group 2 comprised 31 children (7 months to 3 years-old; median = 1.0-year-old) and Group 3 comprised 26 patients (3 to 16 years-old; median = 8.4 years-old). A second, control cohort (Group 4) included 39 non-infected infants (3 days to 5 months-old; median = 31 days-old) born to T . cruzi -infected mothers. Despite its suboptimal seroprevalence (58.4%), α-Gal-ELISA yielded shorter median time values of negativization (23 months [IC 95% 7 to 36 months] vs 60 months [IC 95% 15 to 83 months]; p = 0.0016) and higher rate of patient negative seroconversion (89.2% vs 43.2%, p < 0.005) as compared to conventional serological methods. The same effect was verified for every Group, when analyzed separately. Most remarkably, 14 out of 24 (58.3%) patients from Group 3 achieved negative seroconversion for α-Gal-ELISA while none of them were able to negativize for conventional serology. Detailed analysis of patients showing unconventional serological responses suggested that, in addition to providing a novel tool to shorten follow-up periods after chemotherapy, the α-Gal-ELISA may assist in other diagnostic needs in pediatric Chagas disease. The tools evaluated here provide the cornerstone for the development of an efficacious, reliable, and straightforward post-therapeutic marker for pediatric Chagas disease. The limits of the current criterion for cure, i.e., negative seroconversion determined by conventional serology, and the lack of validated and sensitive markers for early assessment of response to trypanocidal drugs in Chagas disease stress the necessity of novel therapeutic response markers. Towards this goal, we herein developed by synthetic chemistry a neoglycoprotein bearing an α-Gal antigenic surrogate, termed NGP-Tri, and evaluated its performance in a large cohort of T . cruzi -infected and treated children. An α-Gal-ELISA built upon NGP-Tri showed a very good performance on the assessment of therapy efficacy, as it displayed significantly shorter median time value of negativization and higher rate of patient negative seroconversion as compared to conventional serology methods. These findings indicate that the tools developed here, as well as optimized versions derived from them, should have a positive impact on the clinical management of Chagas disease and the identification and/or clinical validation of novel drug candidates for the treatment of T . cruzi infections.

Apolipoprotein A1 and Fibronectin Fragments as Markers of Cure for the Chagas Disease

Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins

Trypanosoma cruzi antigen detection in blood to assess treatment efficacy and cure in mice models of Chagas disease

Small molecule biomarkers predictive of Chagas disease progression

An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi -infected children. A retrospective cohort study

Characterization of Novel Trypanosoma cruzi-Specific Antigen with Potential Use in the Diagnosis of Chagas Disease

Electrochemical Impedance Biosensor for Chagas Disease Diagnosis in Clinical Samples

What are the translational challenges associated with Chagas disease drug discovery?

Accuracy of chimeric proteins in the serological diagnosis of chronic chagas disease – a Phase II study

Tackling the Challenges of human Chagas Disease: a Comprehensive Review of Treatment Strategies in the Chronic Phase and Emerging Therapeutic Approaches

Alternative Approaches for the Treatment of Chagas Disease

Changes in lipid abundance are associated with disease progression and treatment response in chronic Trypanosoma cruzi infection

Loop-Mediated Isothermal Amplification of Trypanosoma cruzi DNA for Point-of-Care Follow-Up of Anti-Parasitic Treatment of Chagas Disease

Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: an individual patient data meta-analysis of two proof of concept trials

Exploring Peripheral Blood-Derived Extracellular Vesicles as Biomarkers: Implications for Chronic Chagas Disease with Viral Infection or Transplantation

Association between altered tryptophan metabolism, plasma aryl hydrocarbon receptor agonists, and inflammatory Chagas disease

Treatment options for Chagas Disease: a systematic review and meta-analysis applied to the preclinical studies using animal models

Parasite Burden of Trypanosoma cruzi in Whole Blood and Buffy Coat Determined by Real-Time PCR in Individuals with Chronic Chagas Disease

Nanomedicines against Chagas disease: a critical review

Molecular detection and parasite load of Trypanosoma cruzi in digestive tract tissue of Chagas disease patients affected by megacolon.